Company News-Bio-Thera Solutions, Ltd.

Bio-Thera Solutions’ Golimumab Biosimilars Receive FDA Approval as First Biosimilars to Simponi® and Simponi Aria®; Accord BioPharma to Commercialize IMMGOLIS™ (golimumab-sldi) and IMMGOLIS INTRI™ (golimumab-sldi) in the United States

2026-05-18

GUANGZHOU, China --- Bio-Thera Solutions (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline...

查看详情

11-272020

Bio-Thera Solutions Submits Marketing Authorization Application (MAA) for BAT1706, a Proposed Biosimilar to Avastin®, to European Medicines Agency (EMA)

GUANGZHOU, China--(BUSINESS WIRE)--Bio-Thera Solutions (SHA: 688177), a commercial-stage biopharmaceuticalcompany, today...
09-252020

Bio-Thera Solutions and BeiGene Announce License, Distribution, and Supply Agreement for Avastin® (Bevacizumab) Biosimilar BAT1706 in China

GUANGZHOU, and BEIJING, China and CAMBRIDGE, Mass, Aug 24, 2020 – Bio-Thera Solutions,Ltd.,a commercial stage biopharmac...
09-252020

Bio-Thera Solutions Partners with Pharmapark to Market BAT2506 in Russia and other CIS Countries

GUANGZHOU, China & MOSCOW--(BUSINESS WIRE)--Bio-Thera Solutions (688177:SH), a commercial-stage biopharmaceutical compan...

上一页 ···25 26 27 28 29 ··· 下一页